IL132941A0 - Composition and method for enhancing transport across biological membranes - Google Patents

Composition and method for enhancing transport across biological membranes

Info

Publication number
IL132941A0
IL132941A0 IL13294198A IL13294198A IL132941A0 IL 132941 A0 IL132941 A0 IL 132941A0 IL 13294198 A IL13294198 A IL 13294198A IL 13294198 A IL13294198 A IL 13294198A IL 132941 A0 IL132941 A0 IL 132941A0
Authority
IL
Israel
Prior art keywords
transport
membrane
polymer
biological
composition
Prior art date
Application number
IL13294198A
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL132941A0 publication Critical patent/IL132941A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13294198A 1997-05-21 1998-05-21 Composition and method for enhancing transport across biological membranes IL132941A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4734597P 1997-05-21 1997-05-21
PCT/US1998/010571 WO1998052614A2 (en) 1997-05-21 1998-05-21 Composition and method for enhancing transport across biological membranes

Publications (1)

Publication Number Publication Date
IL132941A0 true IL132941A0 (en) 2001-03-19

Family

ID=21948441

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13294198A IL132941A0 (en) 1997-05-21 1998-05-21 Composition and method for enhancing transport across biological membranes

Country Status (15)

Country Link
US (5) US6306993B1 (de)
EP (1) EP0975370B9 (de)
JP (1) JP2002502376A (de)
KR (1) KR20010012809A (de)
CN (1) CN1263473A (de)
AT (1) ATE251913T1 (de)
AU (1) AU734827B2 (de)
BR (1) BR9809138A (de)
CA (1) CA2291074C (de)
DE (1) DE69818987T2 (de)
ES (1) ES2210761T3 (de)
GB (1) GB2341390B (de)
IL (1) IL132941A0 (de)
PL (1) PL337033A1 (de)
WO (1) WO1998052614A2 (de)

Families Citing this family (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260006A (zh) 1996-02-26 2000-07-12 加利福尼亚州技术学院 双链dna和杂环低聚物之间复合物的形成
US6090947A (en) 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR20010012809A (ko) * 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
EP1090032A2 (de) 1998-06-20 2001-04-11 Washington University Membran-durchlässige peptid-komplexe für medizinischen bildgebung, diagnostik und therapie
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
JP2003511466A (ja) * 1998-11-11 2003-03-25 パンセコ・アクティーゼルスカブ 修飾ｐｎａ分子
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
DK173006B1 (da) * 1998-11-11 1999-11-01 Ke Burgmann As Fremgangsmåde og anlæg til frembringelse af vægmateriale til brug ved fremstilling af kompensatorer, navnlig til røggaskanaler, samt kompensatormateriale og kompensator frembragt ved fremgangsmåden
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR20020021783A (ko) * 1999-04-05 2002-03-22 밀레니엄 파머슈티컬스 인코퍼레이티드 배합물 어레이 및 그의 용도
DE60033932T2 (de) * 1999-06-05 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation
EP1656945A1 (de) * 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmazeutische Zusammensetzung enthaltend Oligoarginin
MXPA02000890A (es) * 1999-07-28 2003-10-15 Transform Pharmaceuticals Inc Conjuntos de muestras y analisi de alto rendimiento de las mismas para detectar interacciones.
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2001027262A1 (en) * 1999-10-13 2001-04-19 Pantheco A/S Gene selection using pnas
DK1242401T3 (da) 1999-11-24 2007-05-07 Immunogen Inc Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
EP1238071B1 (de) * 1999-11-29 2008-04-23 Avi Biopharma, Inc. Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
WO2001049775A2 (en) * 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
EP1263472A2 (de) 2000-02-15 2002-12-11 Genzyme Corporation Modifizierung von biopolymeren für die verbesserte abgabe von arzneimitteln
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
WO2001074898A2 (en) 2000-03-16 2001-10-11 Genesoft, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
US20040072743A1 (en) * 2000-04-06 2004-04-15 Christensen Jeppe Viggo Pharmaceutical composition of modified pna molecules
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
AU2001257526B2 (en) * 2000-05-04 2007-07-19 Avi Biopharma, Inc. Splice-region antisense composition and method
NZ523719A (en) * 2000-07-21 2004-11-26 Essentia Biosystems Inc Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ATE425457T1 (de) * 2000-10-06 2009-03-15 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
WO2002042316A2 (en) * 2000-11-24 2002-05-30 Pantheco A/S Pna analogues
AU2002216946A1 (en) * 2001-01-05 2002-07-16 Pantheco A/S Modified pna molecules
WO2002065986A2 (en) * 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
AU2002254400B2 (en) 2001-03-23 2007-08-09 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
US7122626B2 (en) 2001-04-26 2006-10-17 Genesoft Pharmceuticals, Inc. Halogen-substitued thienyl compounds
EP1470119A4 (de) 2001-06-13 2005-10-19 Genesoft Pharmaceuticals Inc Benzothiophenverbindungen mit antiinfektiver wirkung
US20030236198A1 (en) 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
EP1401817A4 (de) 2001-06-13 2005-11-02 Genesoft Pharmaceuticals Inc Isochinolinverbindungen mit antiinfektiver wirkung
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
US8815793B2 (en) * 2001-07-20 2014-08-26 Northwestern University Polymeric compositions and related methods of use
US7858679B2 (en) * 2001-07-20 2010-12-28 Northwestern University Polymeric compositions and related methods of use
US7618937B2 (en) * 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US20060264608A1 (en) * 2001-08-03 2006-11-23 Wender Paul A Bi-directional synthesis of oligoguanidine transport agents
US7067698B2 (en) * 2001-08-03 2006-06-27 The Board Of Trustees Of The Leland Stanford Junior University Bi-directional synthesis of oligoguanidine transport agents
JP2005502861A (ja) 2001-08-10 2005-01-27 サイミックス テクノロジーズ， インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
AU2002365136A1 (en) * 2001-10-18 2003-07-30 Essentia Biosystems, Inc. Compositions and methods for controlled release
US7169814B2 (en) 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
AU2002360712A1 (en) * 2001-12-21 2003-07-30 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
DE10201862A1 (de) * 2002-01-18 2003-08-07 Deutsches Krebsforsch Konjugat zur Behandlung prokaryontischer Infektionen
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US20050181474A1 (en) * 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
AU2003219863C1 (en) * 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2003072039A2 (en) * 2002-02-22 2003-09-04 Essentia Biosystems, Inc. Cosmetic formulations containing l-arginine oligomers
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
WO2003092736A2 (en) * 2002-05-01 2003-11-13 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
AU2003290511A1 (en) * 2002-07-11 2004-04-23 The Trustees Of Columbia University In The City Of New York Compositions and methods for the intracellular delivery of antibodies
EP1545462A4 (de) * 2002-07-19 2007-08-08 Univ California Dendrimere als molekulare translokatoren
US20080171012A1 (en) * 2007-01-11 2008-07-17 Phillip Messersmith Fouling Resistant Coatings and Methods of Making Same
US8911831B2 (en) * 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
KR20050032110A (ko) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003259848A1 (en) * 2002-08-15 2004-03-03 Campbell, Samantha A Apicomplexan pathways, inhibitors, and drug delivery
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
US7265129B2 (en) 2002-10-25 2007-09-04 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
AU2003297822A1 (en) 2002-12-10 2004-06-30 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
ES2368941T3 (es) * 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
DK2351844T3 (da) * 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
CN1816346B (zh) * 2003-05-29 2013-04-17 希拉有限责任公司 耐滥用的苯异丙胺化合物
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
US20080311556A1 (en) * 2003-08-07 2008-12-18 Iversen Patrick L Sense Antiviral Compound and Method for Treating Ssrna Viral Infection
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
BRPI0414876A (pt) * 2003-09-30 2006-11-21 New River Pharmaceuticals Inc compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2005046730A2 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Biotin-facilitated transport into gram negative bacteria
CA2553104A1 (en) * 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US20050192210A1 (en) 2004-03-01 2005-09-01 Rothbard Jonathan B. Compositions and methods for treating diseases
EP1734984A4 (de) 2004-03-03 2009-07-29 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen diagnose und therapeutischer transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005218665A1 (en) 2004-03-03 2005-09-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2005118884A1 (en) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
AU2005327188C8 (en) * 2004-07-02 2011-09-22 Avi Biopharma, Inc. Antisense antibacterial method and compound
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US8241651B2 (en) * 2004-11-10 2012-08-14 The Regents Of The University Of Michigan Multiphasic biofunctional nano-components and methods for use thereof
US8043480B2 (en) * 2004-11-10 2011-10-25 The Regents Of The University Of Michigan Methods for forming biodegradable nanocomponents with controlled shapes and sizes via electrified jetting
US7947772B2 (en) * 2004-11-10 2011-05-24 The Regents Of The University Of Michigan Multiphasic nano-components comprising colorants
US7767017B2 (en) * 2004-11-10 2010-08-03 The Regents Of The University Of Michigan Multi-phasic nanoparticles
EP1656951A1 (de) * 2004-11-12 2006-05-17 Xigen S.A. Konjugate mit verbesserter Zellaufnahme
JP2008520764A (ja) * 2004-11-16 2008-06-19 ノースウエスタン ユニバーシティ 防汚表面用ペプチド模倣ポリマー
ES2852549T3 (es) * 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
EP1693458A1 (de) 2005-02-17 2006-08-23 Universite Pierre Et Marie Curie Intrazelluläre Inhibitorpeptide
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CN101160403B (zh) * 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
EP1861112A4 (de) 2005-03-03 2009-07-22 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen
AU2006218455A1 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
US8252754B2 (en) * 2005-03-21 2012-08-28 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
EP1920248B1 (de) 2005-04-05 2010-09-29 Allergan, Inc. Clostridientoxinaktivitätstests
US7973084B2 (en) * 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
KR100699279B1 (ko) 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US20060293268A1 (en) * 2005-05-05 2006-12-28 Rieder Aida E Antisense antiviral compounds and methods for treating foot and mouth disease
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US7538187B2 (en) * 2005-08-01 2009-05-26 E. I. Du Pont De Nemours And Company Coloring compositions with peptide-based dispersants and binders
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
WO2007030576A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7745392B2 (en) * 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
WO2007038171A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007047583A2 (en) 2005-10-18 2007-04-26 National Jewish Medical And Research Center Conditionally immortalized long-term stem cells and methods of making and using such cells
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
FI20055653A (fi) * 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
FI20065030L (fi) * 2006-01-17 2007-07-18 Wallac Oy Neutraaliset leimausreagenssit ja niistä johdetut konjugaatit
US7732539B2 (en) * 2006-02-16 2010-06-08 National Science Foundation Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives
BRPI0708299A2 (pt) * 2006-02-27 2011-05-24 Univ Leland Stanford Junior composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US8563117B2 (en) * 2006-08-04 2013-10-22 Phillip B. Messersmith Biomimetic modular adhesive complex: materials, methods and applications therefore
CA2656681C (en) 2006-08-04 2014-04-22 Nerites Corporation Biomimetic compounds and synthetic methods therefor
JP2010504929A (ja) * 2006-09-27 2010-02-18 ボッティ，パオロ 生体系への送達を高める手段及び方法
CA2672886C (en) * 2006-12-29 2015-02-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
CA2677202A1 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
EP3248985B1 (de) * 2007-01-19 2019-10-23 Kai Pharmaceuticals, Inc. Modifikationen von peptidzusammensetzungen für erhöhte stabilität und ausgabeeffizienz
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US8383092B2 (en) * 2007-02-16 2013-02-26 Knc Ner Acquisition Sub, Inc. Bioadhesive constructs
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2158327B1 (de) * 2007-06-03 2013-05-15 Oncotx, Inc. Tumorassoziierte isoformen von transkriptionsfaktorkomplexkomponenten als biomarker und wirkstofftargets
EP3443976A1 (de) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Gewebespezifische peptidkonjugate und verfahren
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
ES2313848B1 (es) * 2007-10-24 2010-03-22 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Nuevos peptidos antivirales que impiden la union del virus a dlc8.
US20110160146A1 (en) * 2008-02-07 2011-06-30 National Institute of Health (NIH) Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance
CN102937653B (zh) 2008-03-14 2015-09-09 阿勒根公司 基于免疫的血清型a肉毒杆菌毒素活性测定
PL2279008T3 (pl) * 2008-04-18 2020-03-31 Angiochem Inc. Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie
IL287311B2 (en) 2008-05-16 2024-06-01 Taiga Biotechnologies Inc Antibodies and processes for their preparation
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010011641A2 (en) * 2008-07-21 2010-01-28 The Regents Of The University Of Michigan Microphasic micro-components and methods for controlling morphology via electrified jetting
DK2318435T3 (en) 2008-08-28 2016-02-29 Taiga Biotechnologies Inc Modulators of MYC, methods of using the same, and methods for identifying agents that modulate MYC
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US9113836B2 (en) 2009-03-02 2015-08-25 Seventh Sense Biosystems, Inc. Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications
PL2406371T3 (pl) 2009-03-13 2018-11-30 Allergan, Inc. Komórki pomocne w testach do oznaczania aktywności toksyny botulinowej o serotypie a, opartych na immunologii
ES2440597T3 (es) 2009-03-13 2014-03-07 Allergan, Inc. Ensayos de actividad de endopeptidasa re-dirigida basados en inmunología
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
AU2010228091B2 (en) 2009-03-26 2016-06-16 Bl Technologies, Inc. Non-braided reinforced hollow fibre membrane
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
CN102803500B (zh) 2009-06-05 2014-11-19 13治疗有限公司 免疫调节肽和使用方法
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9061250B2 (en) 2009-06-26 2015-06-23 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
EP2448965A4 (de) 2009-07-02 2015-02-11 Angiochem Inc Multimerpeptid-konjugate und deren verwendungen
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
EP4154900A1 (de) 2009-07-29 2023-03-29 Kai Pharmaceuticals, Inc. Therapiemittel zur reduzierung der nebenschilddrüsenhormonspiegel
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US20110130465A1 (en) * 2009-12-01 2011-06-02 Nerites Corporation Coatings for prevention of biofilms
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
WO2011146390A2 (en) 2010-05-17 2011-11-24 The Regents Of The University Of California Compositions and methods for in vivo imaging
TWI620756B (zh) 2010-05-28 2018-04-11 薩羅塔治療公司 具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2011163347A2 (en) 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2012009613A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure environment for fluid transfer devices
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
RU2605251C2 (ru) 2010-09-15 2016-12-20 БиЭл Текнолоджиз, Инк. Способ изготовления армированных нитями половолоконных мембран вокруг растворимого сердечника
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012054841A2 (en) 2010-10-22 2012-04-26 The Regents Of The University Of Michigan Optical devices with switchable particles
US9320826B2 (en) 2010-11-09 2016-04-26 Kensey Nash Corporation Adhesive compounds and methods use for hernia repair
CN103370007B (zh) 2010-11-09 2018-12-18 第七感生物系统有限公司 用于采血的系统和界面
US8529814B2 (en) 2010-12-15 2013-09-10 General Electric Company Supported hollow fiber membrane
JP2012131743A (ja) * 2010-12-22 2012-07-12 Kyoto Univ 腫瘍集積型抗癌剤
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
KR102237667B1 (ko) 2011-04-29 2021-04-12 세븐쓰 센스 바이오시스템즈, 인크. 유체들의 전달 및/또는 수용
JP2014516644A (ja) 2011-04-29 2014-07-17 セブンス センス バイオシステムズ，インコーポレーテッド 血斑または他の体液の収集および／または操作のためのデバイスおよび方法
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP3106092A3 (de) 2011-04-29 2017-03-08 Seventh Sense Biosystems, Inc. Systeme und verfahren zur flüssigkeitsentnahme aus einer person
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012177433A1 (en) 2011-06-21 2012-12-27 Evologie Llc Topical compositions for the treatment of dermatological disorders
WO2013031833A1 (ja) * 2011-08-31 2013-03-07 国立大学法人岡山大学 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
TWI429747B (zh) * 2011-11-02 2014-03-11 Univ Nat Taiwan 具修飾側鏈之ｒｎａ病毒衍生胜肽及其用途
EA035030B1 (ru) 2011-11-18 2020-04-20 Сарепта Терапьютикс, Инк. Модифицированные морфолиновые аналоги олигонуклеотидов
EP2782926B1 (de) 2011-11-24 2018-07-04 Positec Power Tools (Suzhou) Co., Ltd Peptidsequenzentwurf und verwendung davon für peptid-vermittelte sirna-abgabe
US9321014B2 (en) 2011-12-16 2016-04-26 Bl Technologies, Inc. Hollow fiber membrane with compatible reinforcements
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9643129B2 (en) 2011-12-22 2017-05-09 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9022229B2 (en) 2012-03-09 2015-05-05 General Electric Company Composite membrane with compatible support filaments
BR112014022847B1 (pt) 2012-03-16 2022-08-23 Merck Patent Gmbh Lipídios aminoácidos, composição vesicular, e kit
CA2867169C (en) 2012-03-16 2021-07-06 Merck Patent Gmbh Targeting aminoacid lipids
US8999454B2 (en) 2012-03-22 2015-04-07 General Electric Company Device and process for producing a reinforced hollow fibre membrane
JP2015514771A (ja) * 2012-04-17 2015-05-21 ブラウン ユニバーシティ 神経保護性組成物および使用方法
WO2013162729A1 (en) 2012-04-24 2013-10-31 The Board Of Trustees Of The Leland Stanford Junior University Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
SG10201700459XA (en) 2012-07-20 2017-02-27 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9687561B2 (en) 2012-08-14 2017-06-27 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
US9227362B2 (en) 2012-08-23 2016-01-05 General Electric Company Braid welding
EP2920307B1 (de) 2012-11-15 2018-05-02 Roche Innovation Center Copenhagen A/S Anti-apob-antisense-konjugatverbindungen
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用
WO2014169206A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
WO2014169216A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University TEMPLATE-DIRECTED γPNA SYNTHESIS AND γPNA TARGETING COMPOUNDS
KR101447901B1 (ko) * 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR102226110B1 (ko) 2013-06-27 2021-03-10 로슈 이노베이션 센터 코펜하겐 에이/에스 Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
EP2927685A1 (de) 2014-04-02 2015-10-07 Medicyte GmbH Geeignete Hepatozyten für In-vitro-Hepatitistests
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
KR20160001419A (ko) * 2014-06-27 2016-01-06 포항공과대학교 산학협력단 양이온성 분자 수송체 및 음이온성 생리활성 물질을 포함하는 피부 투과용 조성물
WO2016018917A2 (en) 2014-07-28 2016-02-04 The Regents Of The University Of Califoria Compositions and methods of making polymerized nucleic acids
US10980744B2 (en) 2014-08-08 2021-04-20 The Regents Of The University Of California High density peptide polymers
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
CR20200119A (es) 2016-03-14 2021-04-19 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA REDUCIR LA EXPRESIÓN DE PD-L1 (Divisional 2018-0432)
CN109923105A (zh) 2016-09-26 2019-06-21 卡耐基梅隆大学 二价核碱基化合物及其用途
IL281425B (en) 2016-12-02 2022-07-01 Taiga Biotechnologies Inc Nanoparticle formulations
MX2019006882A (es) 2016-12-19 2019-08-16 Sarepta Therapeutics Inc Conjugados de oligomeros de omision de exon para distrofia muscular.
FR3064364A1 (fr) * 2017-03-27 2018-09-28 S.P.C.M. Sa Methode de dosage de polymeres cationiques
CN112996486A (zh) 2017-07-17 2021-06-18 K·罗伊兹曼 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN108822052A (zh) * 2018-05-18 2018-11-16 中国科学技术大学 非肽类多胍小分子和基于非肽类多胍小分子-蛋白质偶联体的蛋白质运输技术
WO2019245353A1 (ko) * 2018-06-22 2019-12-26 재단법인 대구경북과학기술원 사이토카인 융합 폴리펩티드, 및 이를 포함하는 사이토카인 라이브러리
GB201900728D0 (en) * 2019-01-18 2019-03-06 Univ Birmingham Drug delivery system
KR20200110576A (ko) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 사이토카인 기반 면역세포 및 그의 면역 치료 용도
EP3995486A4 (de) 2019-07-02 2023-07-12 Agc Inc. Peptid und verfahren zur herstellung davon
WO2023048236A1 (ja) 2021-09-22 2023-03-30 Ａｇｃ株式会社 ペプチド

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209468A (en) * 1921-03-15 Mitchell William Stocking
US4053638A (en) * 1970-05-06 1977-10-11 William Wrigley Jr. Company Anticaries confectioneries and oral health products
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS55500053A (de) 1978-01-16 1980-01-31
US4847240A (en) 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4880911A (en) 1982-03-19 1989-11-14 G. D. Searle & Co. Fused polypeptides and methods for their detection
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
JP2804273B2 (ja) * 1988-03-09 1998-09-24 株式会社メニコン 高含水性眼用レンズ材料
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5162505A (en) 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
DE69028412T2 (de) 1989-12-21 1997-03-27 Univ Johns Hopkins Med Verfahren zum transport von molekülen in eukaryotenzellen
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5115075A (en) * 1990-05-08 1992-05-19 The Dow Chemical Company Amide and hydroxymethyl functionalized polyethers as thermoplastic barrier resins
US5409764A (en) * 1990-07-17 1995-04-25 Toyo Ink Manufacturing Co., Ltd. Curable adhesive composition and sheet thereof
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5646120A (en) 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
EP0554284B1 (de) * 1990-10-24 1996-12-18 Allelix Biopharmaceuticals Inc. Peptidische hemmer der hiv-replikation
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5831001A (en) 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5633230A (en) 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
AU681997B2 (en) 1991-09-05 1997-09-18 University Of Connecticut, The Targeted delivery of poly- or oligonucleotides to cells
WO1993021941A1 (en) 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0903408A3 (de) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derivate Transport-Polypeptide
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
CA2152387C (en) 1992-12-22 1998-10-27 Michael Twist (Deceased) Synergistic anti-viral compositions
CA2152373C (en) 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
WO1996021036A2 (en) 1994-12-30 1996-07-11 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
CA2252706A1 (en) 1996-05-01 1997-11-06 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5842441A (en) * 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
KR20010012809A (ko) * 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법

Also Published As

Publication number Publication date
WO1998052614A2 (en) 1998-11-26
KR20010012809A (ko) 2001-02-26
US6495663B1 (en) 2002-12-17
CA2291074C (en) 2008-04-01
ES2210761T3 (es) 2004-07-01
CA2291074A1 (en) 1998-11-26
GB2341390A (en) 2000-03-15
US20030162719A1 (en) 2003-08-28
WO1998052614A3 (en) 1999-03-18
US20060111274A1 (en) 2006-05-25
DE69818987T2 (de) 2004-07-29
ATE251913T1 (de) 2003-11-15
EP0975370B1 (de) 2003-10-15
GB2341390B (en) 2000-11-08
US20020131965A1 (en) 2002-09-19
AU734827B2 (en) 2001-06-21
BR9809138A (pt) 2001-08-28
PL337033A1 (en) 2000-07-31
AU7593898A (en) 1998-12-11
EP0975370A2 (de) 2000-02-02
DE69818987D1 (de) 2003-11-20
JP2002502376A (ja) 2002-01-22
GB9923841D0 (en) 1999-12-08
EP0975370B9 (de) 2004-11-03
US6306993B1 (en) 2001-10-23
CN1263473A (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
GB2341390B (en) Composition and method for enhancing transport across biological membranes
MXPA03007358A (es) Transportadores que contienen porciones de arginina separadas.
DK1056477T3 (da) Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
ATE156500T1 (de) Polymerzusammensetzung, absorptionsmaterialzusammensetzung, deren herstellung und verwendung
TR200100139T2 (tr) İntegrinlerin reseptörlerine bağlanmasını inhibe eden N,N-iki ikameli amitler
EE03237B1 (et) Kontrastaine, selle valmistamismeetod ja kasutamine, kopolümeerne pindaktiivne aine, seda sisaldav emulsioon ja nende kasutamine
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
AU3141693A (en) Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
ATE332918T1 (de) Neoglycoproteine
BG101781A (en) Active substance-containing solid preparation
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
CA2230140A1 (en) Compositions and methods for controlling harmful fungi
AU7931301A (en) Method of using diketopiperazines and composition containing them
WO2003068144A3 (en) Cytotoxic agents
EP0743066A3 (de) Wundheilmittel
IE810460L (en) Enzyme inhibitors.
PL338237A1 (en) Pharmaceutic composition containing vitamin d and calcium salt as well as method of obtaining same
EA200500300A1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
IL115138A0 (en) Implantable polymer-containing molded articles for the administration of active substances to plants and processes for the preparation thereof
DE69738185D1 (de) Verfahren zur Herstellung eines bluddrucksenkenden Mittel enthaltenden ein Dipeptid als wirksames Bestandteil
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
WO1996028468A3 (en) Amphiphilic peptide and analogs thereof
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient